EHA – Monthly Dosing of Anti-C5 Antibody Showing Promise in PNH Patients
10 June 2016

Alexion announced data from their Phase 1/2 study testing monthly dosing of the anti-C5 antibody, ALXN1210, in patient with paroxysmal nocturnal hemoglobinuria (PNH) yielded highly significant resu

Olaratumab Almost Doubles Survival Time in Phase 2 Soft Tissue Sarcoma Study
10 June 2016

Eli Lilly is moving quickly with its cancer drug olaratumab to treat patients with advanced soft-tissue sarcoma. And for good reason.
 

Subcutaneous form of GSK lupus drug on target
9 June 2016

GlaxoSmithKline has presented promising late-stage data on a subcutaneous formulation of its lupus drug Benlysta in a subset of patients with highly-active forms of the disease.

EU nod for Avastin/Tarceva lung cancer combo
9 June 2016

The European Commission has approved the use of Roche's Avastin in combination with Tarceva to treat a certain form of lung cancer, marking the first time the drug has been cleared for use alongsid

Study Identifies 11 Subgroups of Acute Myeloid Leukemia
9 June 2016

A new study published in the New England Journal of Medicine may change the way we manage acute myeloid leukemia (AML) patients and how we develop future, more targeted therapies.
 

Trial of AbbVie's Rova-T disappoints at ASCO
7 June 2016

A cancer drug licensed by AbbVie in a $5.8bn deal has failed to impress at this year's ASCO conference, sending the company's shares into decline.

Adding Doxorubicin to Sorafenib Does Not Improve Survival in Advanced Hepatocellular Carcinoma
7 June 2016

Results of a phase III trial questions the value of additional chemotherapy treatment for advanced hepatocellular carcinoma (HCC).

UK launch for first hereditary factor X deficiency treatment
7 June 2016

The first and only treatment licensed specifically for the rare bleeding disorder hereditary factor X deficiency has now been launched across the UK.